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Structured Abstract  
Background The National Institute for Health and Care Excellence (NICE) 
developed a guideline on drug misuse prevention in vulnerable populations. Part of 
the guideline development process involved evaluating cost-effectiveness and 
determining which interventions represented good value for money. 
Methods Economic models were developed for seven interventions which aimed to 
prevent drug use in vulnerable populations. The models compared the costs (to the 
health and crime sectors) and health benefits (in quality-adjusted life years (QALYs)) 
of each intervention and its comparator. Sensitivity analysis explored the uncertainty 
associated with the cost of each intervention and duration of its effect.   
Results The reduction in drug use for each intervention partly offset the costs of the 
intervention, and improved health outcomes (QALYs). However, with high 
intervention costs and low QALY gains, none of the interventions were estimated to 
be cost-effective in the base case. Sensitivity analysis found that some of the 
interventions could be cost-effective if they could be delivered at a lower cost, or if 
the effect could be sustained for more than two years.  
Conclusions For drug misuse prevention to be prioritised by funders, the 
consequences of drug misuse need to be understood, and interventions need to be 
shown to be effective and cost-effective. Quantifying the wider harms of drug misuse 
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and wider benefits of prevention interventions poses challenges in evaluating the 
cost-effectiveness of drug misuse prevention interventions. A greater understanding 
of the consequences of drug misuse and causal factors could facilitate development 
of cost-effective interventions to prevent drug misuse.  
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1. Introduction 
In 2015, the Department of Health in England asked the National Institute for Health 
and Care Excellence (NICE) to develop guidance on drug misuse prevention 
(National Institute for Health and Care Excellence, 2017). The guideline scope 
focussed on interventions targeted at populations who were already using drugs 
occasionally, or were considered at most risk of starting to use drugs. The scope 
considered groups including (but not limited to) those with co-occurring mental health 
problems, those not in education, and children and young people whose parents 
used drugs. The guideline focussed on interventions that aimed to prevent or delay 
drug use and excluded interventions related to the supply of drugs, treatment of drug 
misuse or dependence and interventions to promote safer injecting (National Institute 
for Health and Care Excellence, 2015). 
NICE follows a defined process in developing guidelines that considers evidence for 
the effectiveness and cost-effectiveness of interventions when making 
recommendations (National Institute for Health and Care Excellence, 2016). In 
considering cost-effectiveness evidence, NICE’s preference is usually to conduct 
cost-utility analysis, using quality-adjusted life years (QALYs) as the outcome metric. 
QALYs combine quality of life with length of life, and therefore allow comparison of 
outcomes across different health areas. An incremental cost-effectiveness ratio 
(ICER) can be calculated by dividing the difference in costs of an intervention and its 
comparator by the difference in QALYs. Judging the size of ICERs assists decision 
makers in determining whether an intervention represents good value for money. (It 
should be noted that cost-effectiveness is not the sole factor considered in NICE’s 
decision making, and that other elements such as the fair distribution of resources 
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should also be considered (National Institute for Health and Care Excellence, 
2008a)).   
A systematic review of the literature did not identify any articles that reported 
relevant cost-effectiveness evidence (Bates et al., 2016). Three reports summarising 
findings from a US-based cost-benefit model for interventions targeting relevant 
populations were identified from additional sources, but these were considered to 
have limited applicability to the UK setting. Given the absence of relevant cost-utility 
analysis from the literature, the development of new economic models was 
considered important in understanding which interventions aimed at drug misuse 
prevention represent good value for money. The economic models considered 
behavioural interventions identified in a systematic review of the literature. None of 
the interventions considered in the economic models were considered cost-effective 
using NICE’s standard approach.  
This article aims to explore why these interventions were not cost-effective and how 
future economic evaluations should consider interventions to prevent drug misuse. 
We do this by: 
 providing an overview of the modelling approach and inputs and reporting the 
results of the analysis, 
 providing sensitivity analysis to understand which parameters would need to 
change for interventions to be cost-effective, and 
 discussing the challenges of economic evaluation of drug misuse prevention. 
We draw comparison with alcohol and smoking, and refer to established challenges 
in economic evaluation in public health. We discuss the limitations of our analysis 
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and suggest alternative approaches which could be used in future analyses, and 
areas in which further research would be particularly valuable.  
2. Material and methods 
2.1 General modelling approach 
Economic modelling compares the costs and consequences of two alternative 
courses of action. Models combine data from multiple sources to estimate the total 
costs and benefits that would occur if each of the two courses of action were 
implemented. Decision tree models use ‘branches’ to represent the different 
pathways patients can follow or events that can happen, and multiply the 
probabilities of these events by the costs and consequences of the events (Brennan 
et al, 2006; Briggs et al, 2006; Drummond et al, 2005; Morris et al, 2012). Decision 
trees are commonly used in evaluating the cost-effectiveness of health interventions 
for drug or alcohol problems (Hoang et al., 2016). We developed decision tree 
models to compare the costs and QALYs associated with the change in drug use for 
each intervention and its comparator in the study. We performed literature searches 
to identify the events, costs and consequences which would be included in the 
models. These required numerical data comparing outcomes between drug use and 
non-drug use such as relative risks or odds ratios. Outcomes for which quantifiable 
effects could not be identified were excluded from the models. Included events were 
discussed and agreed with an advisory committee.   
We adopted a partial public sector perspective, including costs to healthcare and 
criminal justice sectors. We did not include costs relating to employment, education 
or out-of-pocket expenses incurred by individuals. We considered health effects to 
the individuals at risk of drug misuse, using QALY losses to capture the impact of 
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both reductions in quality-of-life, and of premature death. The costs and opportunity 
for QALY gains for each intervention were specific to the drug in question, as the 
potential consequences of cannabis, ecstasy and cocaine usage differ and no single 
source was identified which reported data for all drugs. Costs and QALYs were 
discounted at 3.5% per annum (National Institute for Health and Care Excellence, 
2016). All costs were expressed in 2015 prices (GBP). The modelled time horizon 
(time period over which events, costs and consequences are considered) depended 
upon the duration of the study and evidence base for drug-related consequences, 
and was varied in scenario analyses. Details of all the models and inputs are 
available elsewhere (Collins et al., 2016).  
2.2 Interventions 
Interventions identified in a systematic literature review of the effectiveness of 
targeted prevention programmes (Novakovic et al., 2016) were included in the 
models if they reduced drug misuse, the source study included a comparator group, 
and the baseline characteristics of the population in the study were defined. A total of 
seven interventions met these criteria. These were:  
1. Focus on Families: a multicomponent intervention with families of substance 
abusers (Catalano et al., 1999).  
2. A web-based personalised feedback intervention based on brief motivational 
interviewing techniques, for college student cannabis users (Lee et al., 2010). 
3. Familias Unidas: a group based multi-parent intervention for families of 
delinquent youth (Pradoet al., 2012). 
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4. A single brief motivational interviewing session for regular ecstasy users 
(Martin and Copeland, 2010). 
5. A brief motivational interviewing intervention to reduce both risky sex and drug 
use in young gay and bisexual men (Parsons et al.,2014). 
6. A motivational interviewing intervention to reduce club drug and HIV risk 
behaviours use among men who have sex with men (Morgenstern et 
al.,2009). 
7. STRIVE (SupporT to Reunite, Involve and Value Each other): A family-based 
intervention to reduce substance use among newly homeless youth (Milburn 
et al.,2012). 
The effectiveness of the interventions was derived from the effectiveness studies 
identified in the systematic review (Novakovic et al., 2016). Population, intervention, 
comparator and effectiveness data are presented in Table 1. 
None of the studies provided UK costs for the interventions, so we estimated 
intervention costs by converting costs from other currencies to GBP, or by applying 
UK unit costs to reported resource use. UK practice may differ from the source 
studies, and there may be local variation in the implementation of the interventions, 
so the intervention costs were varied in sensitivity analysis. Estimates including 
lower and upper bounds are provided in Table 2. 
[Table 1 to go here] 
[Table 2 to go here] 
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2.3 Models focussing on cannabis use 
Cannabis use was associated with an increased risk of psychotic disorders and of 
being arrested. The models assumed that cannabis use increased the rate of 
psychotic disorders from seven in 1,000 to 14 in 1,000 (Hall, 2015). Annual psychotic 
disorder-related costs included service costs (£13,136) and informal care costs 
(£4,242). Psychotic disorders were assumed to reduce health related quality of life 
from 1 to 0.68 (McCrone et al., 2009) (where 1 is equivalent to full health and 0 is 
equivalent to being dead). It was estimated that there are 50.27 cannabis possession 
arrests per 1,000 cannabis users based on police recorded data from 2014-15, 
costing £500 per arrest. The cost of £500 is based on the average time it takes an 
officer to deal with an offence, noting that that this cost is low as most cannabis 
possessions are assumed not to result in court activity (May et al., 2007).The 
literature indicated that cannabis use may be associated with an increased risk of 
road traffic accidents (Gadegbeku et al., 2011; Harman and Huestis 2013) but the 
advisory committee which developed the guideline was not convinced of the 
robustness of these estimates, and so they were included in sensitivity analysis only. 
Cannabis-related lung cancer was excluded from the models as robust UK data were 
not identified. Our modelled social costs for one year of cannabis use are shown in 
Figure 1.  
Three interventions reported changes in cannabis use: Focus on Families, the web-
based personalised feedback intervention, and Familias Unidas. 
2.3.1 Focus on Families  
Seven percent of children receiving the intervention had used cannabis 12 months 
after receiving Focus on Families, compared nine percent of children in the 
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comparator group (Catalano et al., 1999). The model did not assume any continued 
effect beyond the 12 month time horizon because a follow-up study demonstrated 
that the intervention effect was restricted to 12 months (Haggerty et al., 2008). 
2.3.2 Web-based Feedback 
The study duration was six months (Lee et al., 2010), and we did not identify 
evidence that the duration of effect would be sustained beyond the study period. 
Therefore the base case (most plausible scenario) considered a one year time 
horizon, assuming that cannabis use was reduced at month six and then rebounded 
to baseline at month 12. To explore the sensitivity of the model to this assumption, 
we considered a scenario with a two year time horizon, assuming that cannabis use 
was reduced at month six, and returned to baseline at 24 months. 
2.3.2 Familias Unidas  
The base case considered the 12 month study duration only. Two scenarios 
considered a 24 month time horizon, using the trial data for drug use at baseline, 
month six, 12 and extrapolating for month 18: one scenario assumed drug use 
returned to baseline at month 24, while the other assumed drug use remained 
constant beyond the extrapolated value for month 18. 
2.4 Models focussing on ecstasy use   
Ecstasy use was associated with an increased risk of arrest, hospital admission, 
accident and emergency attendance, ambulance conveyance, death, and drug 
dependence. The models assumed that each ecstasy user consumed 40.75 tablets 
per year, which was calculated from estimates of the number of tablets consumed 
per year, UK population data, and the prevalence of ecstasy use (Collins et al., 
[Insert footer here]  11 of 44 
2016). The model assumed that there are 0.11 sentences per 1,000 ecstasy users, 
costing £23,194 per sentence, and 2.13 arrests per 1,000 ecstasy users, costing 
£1,346 per arrest (Advisory Council on the Misuse of Drugs 2008; Ministry of Justice 
2014). Rates of hospital admission, A&E attendance and ambulance conveyance 
were 2.43, 2.43, and 1.68 per 1,000 users, with unit costs of £372, £109 and £216 
respectively (Department of Health, 2014).  Ecstasy use also carries a risk of death, 
estimated at 0.039 per 1,000 users (Office for National Statistics, 2014) which has a 
cost of £464 to the National Health Service and (discounted) QALY loss of 22.3 for 
16-24 year olds and 17.9 for 25-59 year olds. The risk of ecstasy dependence is 0.68 
per 1,000 users with a cost of £2,620 (Collins et al., 2016). Our modelled social costs 
for one year of ecstasy use are shown in Figure 1.  
Only the brief motivational intervention studied by Martin and Copeland (2010) 
focussed on ecstasy use. 
2.4.1 Brief intervention 
The study (Martin and Copeland, 2010) reported ecstasy use at baseline and month 
three. In the model for the intervention group, we assumed that ecstasy use 
decreased linearly over the first three months for the intervention group, and then 
increased linearly to baseline at 12 months (base case) or 24 months (scenario 
analysis). The model assumed no change in ecstasy use in the comparator group. 
2.5 Models focussing on cocaine use 
Cocaine use was associated with an increased risk of arrest, hospital admission, 
death, and drug dependence. The models assumed that the risk of cocaine-related 
arrest was 9.4 per 1,000 users at a cost of £1,925 per arrest (Godfrey et al., 2002). 
Hospital admissions included cocaine-specific diagnoses with a probability of 2.24 
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per 1,000 users and cost per admission of £1,765, cocaine-related cardiovascular 
admissions with probability 2.20 per 1,000 users and cost per admission of £1,678, 
and cocaine-related myocardial infarctions with probability of 1.39 per 1,000 users 
and cost per event of £3,459 (Godfrey et al., 2002). The probability of being in 
treatment for dependence on cocaine use varies by age – for people aged 16-19 this 
was 12.9 per 1,000 users and for people aged 30-40 this was 3.44 per 1,000 users. 
Drug dependence was assumed to lead to a QALY loss of 0.576 per person (Pyne et 
al., 2011) and a cost of £1,562 for treatment. Cocaine use carries an annual excess 
risk of death of 0.048 per 1,000 users.  The QALY loss for premature death depends 
on age and is 20.9 (discounted) for someone who dies at age 25 and 17.7 
(discounted) for someone who dies at age 39 (Collins et al., 2016). Our modelled 
social costs for one year of cocaine use are shown in Figure 1. 
Three interventions reported change in cocaine use: motivational interviewing in 
young gay and bisexual men, motivational interviewing in men who have sex with 
men, and STRIVE. 
2.5.1 Motivational interviewing to reduce drug use in young gay and bisexual 
men 
The model assumed that drug use changed between the levels reported in the study 
(Table 1) until 12 months (the study duration). Between months 12 and 24, the base 
case assumed that drug use returned linearly to baseline, and a scenario analysis 
extrapolated data from the first 12 months.  
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2.5.2 Motivational interviewing to reduce club drug use among men who have 
sex with men 
The model assumed that the prevalence of drug use changed in line with the days of 
drug use from the study (Table 1) until month 12 (the study duration). Between 
months 12 and 24, the base case assumed that drug use returned linearly to 
baseline, and a scenario analysis extrapolated data from the first 12 months. 
2.5.3 STRIVE 
The model assumed that prevalence of drug use changed in line with days of drug 
use from the study (Table 1), until month 12 (the study duration). Between months 
12 and 24, the base case assumed that drug use returned linearly to baseline, and a 
scenario analysis extrapolated data from the first 12 months. 
[Figure 1 to go here] 
For all of the models, we performed threshold analyses to explore the duration of 
intervention effect needed for each intervention to be cost-effective. 
 
Results 
The base case costs, QALYs and incremental cost-effectiveness ratios (ICERs) for 
each intervention are reported in Table 3. ‘Costs’ refers to both the cost of the 
intervention (or the comparator) and social costs associated with drug misuse. 
‘QALYs’ refers to the QALY losses associated with drug misuse only. For all 
interventions, the base case ICERs are estimated to be above £100,000/QALY, and 
well above the £20,000/QALY level that NICE generally considers for cost-
effectiveness (National Institute for Health and Care Excellence, 2016). This is 
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because the cost savings and QALY gains from reducing drug use are not large 
enough to offset the costs of the interventions.  
The QALY losses for each intervention and comparator are small – in context, a 
QALY loss of 0.00011 equates to losing one hour of life in full health. The QALY 
losses are small because the risk of a person who misuses a drug experiencing an 
event which leads to QALY loss is very low, even though in some cases the QALY 
loss per event (such as premature death) can be substantial. Furthermore, three of 
the interventions (Catalano et al., 1999; Milburn et al., 2012; Prado et al., 2012) are 
delivered to a population where not all recipients at baseline are misusing drugs – 
and so the number of people experiencing a QALY loss is very small indeed. 
Therefore, there is limited potential for interventions to reduce this QALY loss and 
the resulting incremental QALY gain is very small.  
With low incremental QALYs, ICERs are very sensitive to intervention costs, and so 
sensitivity analysis for low and high intervention costs as well as sustained duration 
of effect is presented in Table 4. The web-based feedback intervention, which 
targeted a population who were all occasional drug users at baseline, becomes 
dominant (providing more benefit than comparator at a lower cost) when the cost is 
reduced to £1. At this price, the cost saving from avoiding drug use is sufficient to 
offset the intervention cost. It may be feasible for an online intervention to be 
delivered at such a low cost per person when provided to a sufficiently large 
population. Changing the cost of the Focus on Families intervention does not 
sufficiently decrease the ICER for the intervention to be cost-effective. This is 
because only a small proportion of the study population uses drugs and the 
intervention effect is small. Like Focus on Families, Familias Unidas targets people 
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at risk of drug use, but has a lower intervention cost and higher incremental effect 
than Focus on Families. Familias Unidas would be dominant if the duration of effect 
was sustained and the intervention cost was £116, but the feasibility of delivering an 
intensive intervention with the same effectiveness for such a low cost is unknown. 
The interventions for ecstasy and cocaine use are estimated to be not cost-effective 
even with a low cost and sustained duration of effect. 
The ICERs for Focus on Families and STRIVE remain above £30,000/QALY even in 
a scenario where drug use took over 60 years to return to baseline. The other 
interventions become cost-effective at £20,000 - £30,000/QALY when the duration of 
effect increases.  For motivational interviewing among men who have sex with men 
the duration of effect needs to be 25-45 years, for motivational interviewing in young 
gay and bisexual men and the brief intervention for ecstasy, the duration needs to be 
10-20 years.  Familias Unidas and the web-based feedback are cost-effective with 
durations of 4-8 years, and actually become cost-saving if the effect is sustained for 
11 and 6 years respectively. 
[Table 3 to go here] 
[Table 4 to go here] 
Discussion  
Although interventions may well exist that are cost-effective in preventing drug 
misuse in vulnerable populations, these were not included in the NICE scope and 
none of the interventions considered in our analyses were estimated to be cost 
effective in the base case. This is at least partially due to the relatively low 
effectiveness of the interventions – more robust evidence of larger intervention effect 
sizes would translate into more favourable cost-effectiveness estimates. However, 
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the analyses were additionally subject to a number of limitations, many of which are 
common challenges in the economic evaluation of public health interventions 
(Weatherly et al, 2009). 
Duration of intervention effect 
NICE has found interventions to prevent smoking and alcohol misuse to be cost-
effective (National Institute for Health and Care Excellence, 2010; National Institute 
for Health and Care Excellence, 2008b; National Institute for Health and Care 
Excellence, 2007). However, interventions with similar costs in drug misuse 
prevention and alcohol consumption or smoking have very different cost-
effectiveness results. Interventions that cost £15 per head and prevented smoking 
prevalence by 0.5% were estimated to be cost-effective, with ICERs much lower 
than those for the web-based intervention included in the current analysis, which 
also cost £15 per head (Raikou and McGuire, 2008). Screening to identify people at 
increased risk followed by brief advice costing £80 was estimated to reduce alcohol 
use by 12.3%, and the ICERs varied between being dominant and £6,000/QALY 
(Purshouse et al., 2009). In comparison, the brief intervention to reduce ecstasy use 
had a similar cost and reduced drug use by 32% but had ICERs above 
£200,000/QALY.  
The effect of the screening followed by brief advice for alcohol consumption was 
assumed to return to baseline over seven years (Purshouse et al., 2009), a longer 
duration than the ecstasy brief intervention model (12 months). The cost-
effectiveness of any intervention is sensitive to the duration of effect, and Purshouse 
et al., (2013) found that assuming that the effect returned to baseline over three 
years halved the QALY gain and increased the ICER to £39,000/QALY. We did not 
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identify any evidence to support conducting analyses with longer duration of effect 
for the included interventions and the single study that included longer term follow up 
found no effects beyond 12 months (Haggarty et al., 2008). However, sensitivity 
analysis demonstrated that with duration of effect comparable to that of the brief 
intervention for alcohol, four of the seven interventions could be cost-effective or 
even cost-saving.  
Long-term consequences of drug misuse 
Most interventions to prevent alcohol misuse or smoking are cost-effective partially 
because the long term consequences of smoking and alcohol are well understood 
and avoidable costs are high (Allender et al., 2009; Balakrishnan et al., 2009; Ekpu 
and Brown, 2015; Nutt et al., 2010; Scarborough et al., 2011; Wadd and 
Papadopoulos, 2014). There is high quality evidence linking alcohol and smoking to 
a range of health outcomes such as high blood pressure, heart disease, respiratory 
disease, cancers, digestive disease and road traffic accidents, whereas the evidence 
for the association between illicit drug use and these types of outcomes is much 
weaker. We note that including cannabis-related road traffic accidents in sensitivity 
analyses decreases the ICERs for interventions, for example from £240,994 to 
£205,442 for Familias Unidas.  
The social costs associated with each drug in our analysis are limited by the data 
available, although we note that all were validated through discussion with a 
committee of experts. This relative paucity of data is likely a feature of the 
comparatively lower drug usage rates in the general population: 2.2% of adults are 
frequent illicit drug users (Home Office, 2015) compared with 19% of adults who 
smoke cigarettes (Office for National Statistics, 2014a) and 79% who drink alcohol 
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(Office for National Statistics, 2014b). The illicit status of drugs may also lead to 
underreporting and further limit the accuracy of estimates. Changes in drug purity, 
potency, and the use of substitute and excipient compounds in some drug 
preparations also presents additional challenges in understanding their long-term 
consequences (Cole et al., 2011). For example, there has been a change in the ratio 
of cannabinoids in analysed samples of cannabis over the last two decades, which 
may have implications for assessments of psychosis risk (Elsohly et al., 2016). 
Our models did not consider the ‘gateway theory’ that early adolescent use of 
cannabis, ecstasy or cocaine can lead to later use of drugs such as opiates which 
have much greater social costs. Evidence for gateway effects are weak (Degenhardt 
et al., 2010; Nkansah-Amankra and Minelli, 2016), but if a causal link does exist then 
our models would underestimate the benefits and cost-effectiveness of drug misuse 
prevention programmes. In addition, our models considered illicit drug use in 
isolation of alcohol and tobacco use. Unhealthy behaviours often cluster together 
and have a magnified combined effect, so drug use may increase the liver damage 
seen with alcohol use (Degenhardt and Hall, 2012), or cannabis use may increase 
the lung damage seen with tobacco use, and may lead to nicotine dependence (Lee 
and Hancox, 2011). 
Appropriateness of the QALY as an outcome  
There are harmful effects of drug misuse which our economic models have not 
captured. Although we include costs related to crime, drug misuse may also have 
(indirect) impact upon attendance and attainment in education and employment, and 
an effect on family and social problems (Lynskey and Hall, 2000; Chatterji 2006; 
Fergusson et al., 2003; Zhang et al., 2006). These would all impact quality of life in a 
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way that health-focussed QALYs do not capture. We considered the harms and 
costs associated with the individual using drugs, but there are also economic, health, 
and social consequences of involvement in illicit drug market and criminal justice 
system (United Nations Office on Drugs and Crime, 1998). Although presentation of 
a cost-utility analysis facilitates comparison with interventions in other health-related 
areas, and allows NICE to apply decision making criteria for recommending 
interventions, this approach may not always capture the full range of relevant 
outcomes in a particular domain. This may be why so few studies were identified in 
the literature review of cost-effectiveness evidence.  
Perspective of analyses and inclusion of wider outcomes 
Our analysis considered only costs to the healthcare and criminal justice systems 
and health effects to the individual. Drug misuse may additionally impact 
productivity, through difficulty in finding or maintaining employment, absenteeism 
and presenteeism, or through premature death. We considered a scenario in the 
models focussing on ecstasy and cocaine use where premature death was 
associated with a loss of earnings, assuming that people would otherwise work until 
age 65, using mean annual salaries by age band (Office for National Statistics, 
2016). In this scenario, the ICERs decreased to £445,274 for the brief intervention, 
£442,324 for motivational interviewing in young gay and bisexual men, £178,805 for 
motivational interviewing in men who have sex with men and £959,695 for STRIVE. 
These small changes to the ICER demonstrate that the inclusion of lost productivity 
due to death would not change the conclusions of the economic models. This is 
because although the cost of lost productivity for one death is relatively high 
(£617,966 for a 25-year-old), it is only incurred by a very small proportion of the 
population receiving the intervention.  Quantifying and including suffering of family 
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and friends would have increased the negative outcomes associated with drug 
misuse for a greater proportion of the population, but if the per-person impact was 
relatively low, this would also have little impact on the ICERs.The interventions 
included in our analyses did not all focus solely on reducing drug use. Arguably, in 
calculating whether an intervention is cost-effective, we should consider the 
potential costs and benefits of its effect on all reported outcomes. Five studies 
additionally measured changes in risky sexual behaviour (Martin and Copeland, 
2010; Milburn et al, 2012; Parsons et al., 2014; Prado et al., 2012). Decreases in 
risky sexual behaviour may lead to reductions in sexually transmitted infections and 
unwanted pregnancies. Incorporating such additional outcomes would be likely to 
increase the cost offsets and QALY gains for the interventions and hence decrease 
the ICERs, possibly to such a level that the interventions become cost-effective.  
Furthermore, the interventions may have reduced use of more than one drug, which 
would deliver additional QALY gains and cost offsets for the same intervention cost, 
therefore decreasing the ICER. Interventions which additionally reduced use of 
injectable drugs such as heroin may lead to reductions in needle-sharing and hence 
avoid transmission of disease such as hepatitis, which would have further benefits.   
Our study focussed on interventions which targeted high-risk populations. There are 
strong associations between problematic drug use, socioeconomic disadvantage, co-
morbidities, and other vulnerabilities (e.g. homelessness) (Daniel et al., 2009; PHE, 
2016). It is difficult to disaggregate the effect of an individual’s drug use from other 
risk factors in contributing to harmful outcomes and so primordial prevention of risk 
factors, as well as actions to reduce the influence of these risk factors, may impact 
upon multiple outcomes (Wilkinson and Pickett, 2010). The models we developed 
considered the differential distribution of drug use in study populations, but there was 
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not sufficient evidence in primary studies to consider differential outcomes in detail. 
So, for example, the modelling took into account the increased likelihood that 
someone who was homeless was more likely to use drugs, but not that they might be 
more likely to be arrested than a drug user who was not homeless, or that 
intervention participation also increased the (unmeasured) likelihood that the 
individual would find stable housing. 
There is little high-quality review-level evidence on the effectiveness of selective 
drug prevention programmes (Novakovic et al., 2016) However, there are multiple 
levels of influence that might potentially reduce the propensity to use drugs (Griffin 
and Botvin, 2010) in higher risk groups. These include psychobiological, social, 
family, and socioecological factors, and so programmes designed to improve 
outcomes in these domains, although not specified as drug prevention programmes, 
may have indirect effects on drug use. For example, the Good Behaviour Game is a 
universal elementary school classroom behaviour management intervention, and 
participation has been found to be associated with lower rates of drug and alcohol 
use disorders, regular smoking, antisocial personality disorder, criminal justice 
involvement and suicide ideation in late adolescence (Kellam et al., 2011). 
Secondary analysis suggested that intervention impact might be more pronounced in 
those participants rated at higher risk at baseline (Kellam et al., 2014). Inclusion of 
data from some universal programmes and including a wider range of outcomes in 
economic evaluation may lead to further cost savings and health benefits, and 
therefore improve the cost-effectiveness of the intervention.  
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Targeting interventions  
The interventions considered here, as with many public health interventions, are 
aimed at prevention rather than treatment. This means that costs are incurred by a 
whole population, but only a proportion of that population is actually affected as not 
all would experience long term drug-related harms. Better targeted interventions at 
those sub-populations most at risk of experiencing drug related harms could 
increase the proportion of recipients who benefit from the interventions studied, and 
therefore increase the cost-effectiveness of interventions.  However, this requires 
that the interventions under review have differential effectiveness for higher risk sub-
groups. Whilst analysis of other prevention programmes has shown this to be the 
case (Conduct Problems Prevention Research Group, 2007; Kellam et al., 2008; 
McKay et al., 2014), others have not (Botvin et al.,1998; Elliott and Mihalic, 2004; 
Komro and Toomey, 2008; Spoth et al., 2006), and without secondary analysis of the 
programmes included in the current review, differential effects cannot be assumed.   
Conclusion 
Our analysis estimated that none of the seven drug misuse prevention interventions 
were cost-effective in the base case, because the cost savings and health benefits 
from preventing drug use did not sufficiently offset the intervention costs. Sensitivity 
analyses demonstrated that some interventions were cost-effective when a longer 
duration of intervention effect was assumed, demonstrating the importance of long-
term follow up. Similarly, intervention cost was a key driver of cost-effectiveness, 
indicating that consideration should be given to the resources required to deliver the 
interventions in specific settings.  
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The ICERs for some interventions remained high even under more optimistic 
assumptions about duration of effect and intervention cost. This may be because in 
these cases, the intervention effect size was not sufficiently large to generate 
benefits to outweigh the cost. Inclusion of a broader range of benefits has the 
potential to reduce the ICERs somewhat, but may not have a substantial impact 
because only a fraction of people receiving the intervention are affected by serious 
consequences.  A greater understanding of the consequences of drug misuse and 
the causal factors may facilitate the targeting of interventions to the most vulnerable 
populations and lead to more favourable cost-effectiveness results. 
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Tables 
Table 1: intervention data 
Study Population Intervention Comparator Modelled intervention 
effectiveness 
Modelled comparator  
effectiveness 
Study – Focus on Families 
Intervention 
(Catalano et al., 1999) 
Children whose parent use 
drugs 
Family-based 
intervention: group 
skills training for 
parents and case 
management 
Standard 
methadone 
treatment 
Cannabis use was 7% after 
12 months 
Cannabis use was 9% 
after 12 months 
A Brief, Web-Based Personalized 
Feedback Selective Intervention for 
College Student Marijuana Use: A 
Randomized Clinical Trial 
(Lee et al., 2010) 
People known to use drugs 
occasionally  
(subgroup analysis for 
people with family history 
of drug use problems) 
Web-based 
intervention based on 
motivational 
interviewing and skills 
training 
Assessment only 
control 
Cannabis use reduced by 
37% after month 6, 25% 
after month 12 and 13% 
after month 18 
No change from 
baseline 
The efficacy of Familias Unidas on 
drug and alcohol outcomes for 
Hispanic delinquent youth: Main 
effects and interaction effects by 
parental stress and social support 
(Prado et al., 2012) 
children and young people 
who are in contact with 
young offender teams but 
not in secure environments 
Family-based 
intervention: group 
skills training for 
parents 
Community 
Practice 
Reduction in drug use from 
27% at baseline to 16% 
and 10% at month 6 and 
month 12 respectively 
Reduction from 32% to 
26% at month 6, and 
then an increase to 36% 
at month 12 
Brief intervention for regular ecstasy 
(MDMA) users: Pilot randomized trial 
of a Check-up model 
(Martin et al., 2010) 
People known to use drugs 
occasionally 
 
Single session 
motivational and 
cognitive behavioural 
intervention 
Assessment only 32.6% reduction in ecstasy 
use at three months 
No change from 
baseline 
A randomized controlled trial utilizing 
motivational interviewing to reduce 
HIV risk and drug use in young gay 
and bisexual men 
people who are lesbian, 
gay, bisexual or 
transgender 
Motivational 
interviewing 
Educational 
videos and 
structured 
discussion  
Drug use at baseline, 3, 6, 
9 and 12 months 82.2%, 
68.9% 63%, 52.7% and 
55.9% 
Drug use at baseline, 3, 
6, 9 and 12 months  
80%, 71%, 74.5%, 
61.4% and 61.1% 
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(Parsons et al., 2014)  
Randomized Trial to Reduce Club 
Drug Use and HIV Risk Behaviors 
Among Men Who Have Sex With 
Men 
(Morgenstern et al., 2009) 
people who are lesbian, 
gay, bisexual or 
transgender 
 
Motivational 
interviewing 
Educational 
videos 
Days of drug use at 
baseline, 3, 6, 9 and 12 
months 17, 11, 9, 10, and 6 
Days of drug use at 
baseline, 3, 6, 9 and 12 
months 17, 14, 15, 12 
and 11 
A family intervention to reduce 
sexual risk behavior, substance use, 
and delinquency among newly 
homeless youth (STRIVE) 
(Milburn et al., 2012) 
People who are considered 
homeless 
Group skills training for 
parents and children Standard care 
Days of drug use at 
baseline, 3, 6, 9 and 12 
months were 2.8, 1.3, 0.7, 
0.5, and 0.3 
Days of drug use at 
baseline, 3, 6, 9 and 12 
months 2.7, 1.5, 2, 1.6 
and 1.2 
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Table 2: Intervention costs 
Drug Study 
Intervention cost estimate per 
client  
(low, high) 
Cannabis  Study – Focus on Families Intervention 
(Catalano et al., 1999) 
£3,367 
(£842, £4,209) 
A Brief, Web-Based Personalized Feedback Selective Intervention for College 
Student Marijuana Use: A Randomized Clinical Trial 
(Lee et al., 2010) 
£15 
(£1, £30) 
The efficacy of Familias Unidas on drug and alcohol outcomes for Hispanic 
delinquent youth: Main effects and interaction effects by parental stress and 
social support  
(Prado et al., 2012) 
£154 
(£116, £193) 
 
Comparator  
£100  
(£75, £125) 
Ecstasy Brief intervention for regular ecstasy (MDMA) users: Pilot randomized trial of 
a Check-up model 
(Martin et al., 2010) 
£67 
(£32, £138) 
Cocaine  A randomized controlled trial utilizing motivational interviewing to reduce HIV 
risk and drug use in young gay and bisexual men 
(Parsons et al., 2014) 
£268  
(£128, £552) 
Randomized Trial to Reduce Club Drug Use and HIV Risk Behaviors Among 
Men Who Have Sex With Men 
(Morgenstern et al., 2009) 
 £268  
(£128, £552) 
A family intervention to reduce sexual risk behavior, substance use, and 
delinquency among newly homeless youth (STRIVE) 
(Milburn et al., 2012) 
£825 
(£619, £1,031) 
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Table 3: Base case results 
 
Costs QALYs Incremental Costs Incremental QALYs ICER 
Cannabis: Focus on Families 
Intervention £1,986* -0.000070    
Comparator £7 -0.000090 £1,979 0.000020 £99,254,920 
Intervention 
Comparator £21 -0.000176 £8 0.000017 £478,296 
Intervention £29 -0.000160    
Cannabis: Familias Unidas  
Intervention £164 -0.000113    
Comparator £123 -0.000281 £40 0.000168 £240,994 
Ecstasy: brief intervention  
Intervention £75 -0.000689    
Comparator £10 -0.000827 £65 0.000139 £471,799 
Cocaine: motivational interviewing in young gay and bisexual men  
Intervention £339 -0.013035    
Comparator £75 -0.0136282 £265 0.000588 £450,471 
Cocaine: motivational interviewing among men who have sex with men  
Intervention £340 -0.005668    
Comparator £88 -0.006943 £252 0.001275 £197,623 
Cocaine: STRIVE family intervention among newly homeless youth  
Intervention £834 -0.002464    
Comparator £12 -0.003313 £822 0.000850 £967,573 
*Assuming 1.7 children per family 
ICER: incremental cost-effectiveness ratio, QALYs: quality adjusted life years 
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Table 4: Sensitivity analysis: base case and two year duration with varying intervention costs 
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ICER: low 
intervention cost  
ICER: mean 
intervention 
cost  
ICER: high intervention cost 
Cannabis: Focus on Families £24,761,038 £99,254,920 £124,096,048 
Cannabis: Web-based 
feedback(base case) 
Dominant £478,296 £1,011,468 
Cannabis: Web-based 
feedback(two year reduction 
scenario) 
Dominant £213,221 £481,318 
Cannabis: Familias Unidas (base 
case) 
£12,828 £240,994 £472,142 
Cannabis: Familias Unidas (two 
year reduction scenario 1) 
Dominant  £128,162 £278,716 
Cannabis: Familias Unidas (two 
year reduction scenario 2) 
Dominant  £108,644 £245,257 
Ecstasy: brief intervention (base 
case) 
£219,138 £471,799 £984,340 
Ecstasy: brief intervention (two 
year reduction scenario) 
£104,357 £231,477 £489,347 
Cocaine: motivational 
interviewing in young gay and 
bisexual men (base case) 
£212,291 £450,471 £933,636 
Cocaine: motivational 
interviewing in young gay and 
bisexual men (two year reduction 
scenario) 
£66,262 £144,722 £303,884 
Cocaine: motivational 
interviewing among men who 
have sex with men (base case) 
£87,784 £197,623 £420,439 
Cocaine: motivational 
interviewing among men who 
have sex with men (two year 
reduction scenario) 
£45,026 £108,098 £236,045 
Cocaine: STRIVE family 
intervention among newly 
homeless youth (base case) 
£725,080 £967,573 £1,210,066 
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Cocaine: STRIVE family 
intervention among newly 
homeless youth (two year 
reduction scenario) 
£504,483 £673,562 £842,642 
ICER: incremental cost-effectiveness ratio 
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Crime costs 
 
 
 
Cocaine Value of QALYs lost 
 
 
 
Substance specific hospital 
costs 
 
 
 
Cannabis 
Drug treatment costs 
 
 
 
 
 
 
 
 
Ecstasy 
Substance-related 
cardiovascular hospital 
costs 
Psychosis health service 
costs 
 
Psychosis informal care 
costs 
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